

28 July 2024

Graft Polymer (UK) Plc
(the "Company", "GPL", "Graft Polymer" or "Group")

Results of Annual General Meeting

Graft Polymer (UK) Plc (LSE: GPL), an innovative developer of biopolymer drug delivery systems aimed at enhancing the effectiveness of therapeutics for biopharmaceutical companies, is pleased to announce that all resolutions proposed at the Annual General Meeting of the Company held earlier today were duly passed.

The numbers of proxy votes received in advance of the meeting for each resolution are presented below:

Resolutions	Total For (i)		Total Against		Votes Total
	No. of votes	% of vote	No. of votes	% of vote	
Resolution 1	40,983,414	100.00%	-	-	40,983,414
Resolution 2	40,983,414	100.00%	-	-	40,983,414
Resolution 3	40,983,414	100.00%	-	-	40,983,414
Resolution 4	40,983,414	100.00%	-	-	40,983,414
Resolution 5	40,983,414	100.00%	-	-	40,983,414
Resolution 6	40,983,414	100.00%	-	-	40,983,414
Resolution 7*	40,983,414	100.00%	-	-	40,983,414
Resolution 8*	40,947,383	99.91%	36,031	0.09%	40,983,414

Notes:

i The "For" Proxy vote includes those giving the Chair of the AGM discretion

*Special resolutions

The full text of the resolutions can be found in the Notice of Annual General Meeting, which is available on the Company's website at: <https://graftpolymer.com/shareholder-circulars/>

Enquiries:

Graft Polymer (UK) Plc:

Anthony Tennyson, CEO and Executive Director: anthonytennyson@graftpolymer.com

Yifat Steuer, CFO and Executive Director: yifat@graftpolymer.com

Allenby Capital (Broker):

Phone: +44 (0) 20 3328 5656

Nick Naylor / Liz Kirchner (Corporate Finance)

Guy McDougall (Sales)

About Graft Polymer (UK) Plc

Graft Polymer (UK) Plc (LSE: GPL) is an innovative developer of biopolymer drug delivery systems dedicated to assisting biopharmaceutical companies in enhancing the effectiveness of their therapeutics. Our proprietary patented platform, a bioabsorbable self-nanoemulsifying drug delivery system (SNEDDS), represents a cutting-edge solution in drug delivery technology. By integrating active pharmaceutical ingredients (APIs) into our novel, patented delivery systems, we enable clients to improve the bioavailability, pharmacokinetics, and stability of their therapeutics.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGUWVARSWUNUAR